Abstracts tagged "morbidity and mortality"

Abstract Number: 1431 • 2014 ACR/ARHP Annual Meeting
Influence of Radiographic Joint Damage in Mortality Risk in a Cohort of Rheumatoid Arthritis Patients: A 20 Years Survival Study
L. Rodriguez-Rodriguez^1,2, J. Ivorra-Cortes³, Lydia Abasolo^1,4, Leticia Leon^1,4, Oscar Fontsere⁵, B. Fernández-Gutiérrez^1,5 and Juan A Jover^1,4, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ³Rheumatology, University Hospital la Fe, Valencia, Spain, ⁴Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased mortality and reduced life expectancy compared with the general population. This mortality gap…
Abstract Number: 1391 • 2014 ACR/ARHP Annual Meeting
Weight Loss and Risk of Death in Rheumatoid Arthritis
Joshua Baker¹, Erica Billig², Grant W. Cannon³, Liron Caplan⁴, Vikas Majithia⁵ and Ted R. Mikuls⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁴Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ⁵Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Low body mass index (BMI) has been linked to greater mortality among patients with Rheumatoid Arthritis (RA). Weight loss has also been associated with…
Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting
Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010
Eric Y Yen¹, Magda Shaheen², Jennifer MP Woo³, Deborah K. McCurdy⁴ and Ram Raj Singh⁵, ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CA, ³UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁵Medicine, UCLA Division of Rheumatology, Los Angeles, CA
Title: Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose: Many epidemiologic studies of systemic…
Abstract Number: 817 • 2014 ACR/ARHP Annual Meeting
Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years
I.M. Markusse¹, L. Dirven², J.H. van Groenendael³, K.H. Han⁴, H.K Ronday⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Fransiscus Hospital, Roosendaal, Netherlands, ⁴Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁵Rheumatology, Haga Hospital, The Hague, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁸Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Recent studies showed diverging results about mortality trends in patients with rheumatoid arthritis (RA). Our aim was to determine survival after 10 years of…
Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting
Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Anna-Maria Hoffmann-Vold¹, Oyvind Midtvedt², Torhild Garen³, May Brit Lund⁴, T. Mogens Aalokken⁵, Jan Tore Gran² and Oyvind Molberg⁶, ¹Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁴Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, ⁵Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…
Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting
Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study
Matthew Cascino¹, Laura Trupin¹, Sara Murray¹, Mary Margaretten², Edward H. Yelin³ and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…
Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting
Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Chris T. Derk¹, Nora Sandorfi², Shivani Purohit³ and Christopher Mecoli⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ³Rheumatology Division, Department of Medicine, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…
Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting
Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Inmaculada del Rincon¹, Roy W. Haas², Jose Felix Restrepo³, Daniel F. Battafarano⁴, Daniel H. O'Leary⁵, Emily Molina¹ and Agustin Escalante⁶, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ⁵Radiology, Tufts University-Boston Campus, Boston, MA, ⁶Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…
Abstract Number: 2673 • 2013 ACR/ARHP Annual Meeting
Mortality In Clinically Relevant Osteoarthritis and Rheumatoid Arthritis Compared With The General Population
Aleksandra Turkiewicz¹, Tuhina Neogi², George Peat³ and Martin Englund⁴, ¹Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Research Institute for Primary Care & Health Sciences, Keele University, Keele, United Kingdom, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: There is strong evidence in support of increased mortality in patients with rheumatoid arthritis (RA), while the relation is more controversial in osteoarthritis (OA).…
Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Elizabeth Volkmann¹, Rajan Saggar², Bryant Torres¹, Lynne Yoder², Robert Elashoff³, Rajeev Saggar⁴, Harsh Agrawal¹, Nabeel Borazan⁵, Sarah Thomas¹ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomath, University of California, Los Angeles, Los Angeles, CA, ⁴Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁵Medicine, Rheumatology UCLA, Los Angeles, CA
Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…
Abstract Number: 1698 • 2013 ACR/ARHP Annual Meeting
Sex-Related Differences and Trends In Mortality Of Juvenile-Onset Systemic Lupus Erythematosus (SLE) In The United States Over The Last Forty Years, 1971-2010
Eric Y. Yen¹, Jennifer M.P. Woo² and Deborah K. McCurdy³, ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA
Background/Purpose: To date, SLE-specific mortality studies in children and adolescents are few. Estimations of mortality in adult cohorts of SLE patients have shown that male…
Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Joanna Robson¹, Helen Doll², Ravi Suppiah³, Oliver Flossmann⁴, Lorraine Harper⁵, Peter Hoglund⁶, David Jayne⁷, Alfred Mahr⁸, Kerstin Westman⁹ and Raashid A. Luqmani¹⁰, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²Department of Population Health, University of East Anglia, Norwich, United Kingdom, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁶Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, ⁷Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁸Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ⁹Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…
Abstract Number: 1410 • 2012 ACR/ARHP Annual Meeting
Relationship Between Individual Organ Damage and Mortality of Systemic Lupus Erythematosus (SLE): A Prospective Cohort Study of 679 Patients
Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the relationship between damage in different organ systems and mortality in patients with SLE. Methods: 679 patients who fulfilled at least 4…
Abstract Number: 936 • 2012 ACR/ARHP Annual Meeting
Autoimmune Diseases: Declining Mortality Between 1999 and 2008 However Continuing to be a Leading Cause of Death in Children-A 10-Year Retrospective Review
Eric Y. Yen¹ and Deborah K. McCurdy², ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA
Background/Purpose: Autoimmune diseases are chronic illnesses that cause significant and chronic disability in children and may lead to death. Using mortality data from 1995, Walsh…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].